Why Sardocor
Sardocor is dedicated to the clinical development of novel therapies for patients with devastating common and rare diseases.
- Foundational science by pioneers who established the field of cardiac gene therapy 3 decades ago.
- Using Novoheart's bioengineered human heart-based assays for disease modelling and therapeutic discovery.
- Sardocor aspires to create the shortest regulatory path to effective next-generation gene therapies.
- Proprietary delivery method to the heart for enhancing effectiveness and reducing side effects.
Sardocor at a glance
No IV's
No Toxicity
Highly Targeted
No Immunogenicity
Our Clinical Trials
Sardocor has obtained open Investigational New Drug (IND) approvals from The United States Food and Drug Administration (FDA) for three gene therapy clinical trials.
Heart Failure with reduced Ejection Fraction (HFrEF)
Heart Failure with preserved Ejection Fraction (HFpEF)
Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM)
Pioneering Delivery
> 1,000 doses of SRD001 have been manufactured and been made available to patients.
Our proprietary intracoronary delivery method to infuse gene therapy drug right into the heart has been uniquely designed to use the least amount drugs for efficacy while avoiding side effects.
Investors
JOIN A GROUP OF
REVOLUTIONARY STARTERS
Sardocor is on the lookout for investor relationships that can mutually benefit
our science, propel innovation and investment.
Sardocor strives to improve the quality of life in patients afflicted with incurable diseases with next-generation cell and gene therapy.
2024 All Rights Reserved | Sardocor, a division of Medera
website design by
boston web partners